3只股票，被ST

Core Viewpoint - Several A-share companies are facing risk warnings due to violations related to false disclosures in their financial reports, leading to temporary trading suspensions and changes in stock designations to "ST" [1][4][7][11]. Group 1: Company Specifics - Xiangxue Pharmaceutical will be designated as "ST Xiangxue" after receiving a notice from the China Securities Regulatory Commission (CSRC) regarding false disclosures in its 2019 annual report, which included significant omissions related to related party non-operating fund occupation from 2016 to 2020 [4][6]. - Langyuan Co. will be designated as "ST Langyuan" following a similar notice from the Shandong Securities Regulatory Bureau, which identified false disclosures in its 2019 annual report, including inflated revenue and profits due to non-commercial contracts [8][9]. - Lianchuang Co. will also be designated as "ST Lianchuang" after receiving a notice indicating false disclosures in multiple reports from 2017 to 2019, particularly related to the acquisition of Shanghai Aotou and inflated financial figures [12][14]. Group 2: Regulatory Actions - The CSRC plans to impose penalties on Xiangxue Pharmaceutical, including a warning and a fine of 6 million yuan, along with individual fines for responsible parties [5][6]. - Langyuan Co. faces a proposed fine of 5 million yuan and individual penalties for executives, with significant market bans for key individuals [10]. - Lianchuang Co. is expected to receive a warning and a fine of 600,000 yuan, with severe penalties for responsible executives, including lifetime market bans for some [14].